相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
J. Bae et al.
LEUKEMIA (2018)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez et al.
TARGETED ONCOLOGY (2018)
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
Raghav Sundar et al.
BMC CANCER (2018)
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
Cindy Varga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Martin Koehler et al.
CANCER (2018)
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
Jeremy D. Waight et al.
CANCER CELL (2018)
Present status and future perspective of peptide-based vaccine therapy for urological cancer
Wataru Obara et al.
CANCER SCIENCE (2018)
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017
Evangelos Terpos
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
Eric Sanchez et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro
Ngoc Pham Minh et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Jooeun Bae et al.
LEUKEMIA (2018)
Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy
Prajakta Shinde et al.
SCIENTIFIC REPORTS (2018)
Approaches to Improve Chemically Defined Synthetic Peptide Vaccines
Brett J. Hos et al.
FRONTIERS IN IMMUNOLOGY (2018)
Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
Guoying Zhou et al.
ONCOIMMUNOLOGY (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus (vol 28, pg 228, 2017)
P. Musto et al.
ANNALS OF ONCOLOGY (2018)
Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions
John Berry et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
Adoptive cell therapy in multiple Myeloma
Sonia Vallet et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer
Yoshiyuki Fujiwara et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma
Rebecca Karp Leaf et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Sathana Dushyanthen et al.
NATURE COMMUNICATIONS (2017)
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
Kayoko Waki et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Trial watch: Immune checkpoint blockers for cancer therapy
Claire Vanpouille-Box et al.
ONCOIMMUNOLOGY (2017)
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer
Shinjiro Sakamoto et al.
CLINICAL LUNG CANCER (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Lydia Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer
Hengli Dou et al.
ONCOLOGY LETTERS (2016)
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells
Carolyne Falank et al.
FRONTIERS IN ENDOCRINOLOGY (2016)
Vaccination of multiple myeloma: Current strategies and future prospects
Alessandro Allegra et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Validity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients
Jun-Xia Cao et al.
CYTOTHERAPY (2015)
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies
Rebecca Karp Leaf et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
J. Bae et al.
LEUKEMIA (2015)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2014)
Immunotherapy Strategies in Multiple Myeloma
Jooeun Bae et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
Eva Rossmann et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA
Christine M. Coquery et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2013)
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
Jooeun Bae et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
Jooeun Bae et al.
CLINICAL CANCER RESEARCH (2012)
Active-specific immunotherapy of human cancers with the heat shock protein Gp96urevisited
Marco Randazzo et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders
Jooeun Bae et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma
J. Bae et al.
LEUKEMIA (2011)
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
R Bellucci et al.
BLOOD (2005)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells
LG Ng et al.
JOURNAL OF IMMUNOLOGY (2004)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
分享论文
